⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8224658 | 0.97 | — | — | |
| SCHEMBL29405689 | 0.79 | — | — | |
| SCHEMBL20377718 | 0.78 | SLC7A5 (0.36) | — | |
| SCHEMBL14534555 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL20377736 | 0.75 | SLC7A5 (0.35) | — | |
| SCHEMBL15786203 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL18586753 | 0.73 | — | — | |
| SCHEMBL3892908 | 0.73 | — | — | |
| SCHEMBL20550625 | 0.73 | — | — | |
| SCHEMBL29448013 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| CN-114126619-B | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023185073-A1 | PARP7 INHIBITOR AND USE THEREOF | 诺沃斯达药业(上海)有限公司 | 2023-10-05 | — | — | WO | disclosed |
| CN-116490517-A | Host cells overexpressing translation factors | 龙沙有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230159450-A1 | DIMERS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2023-05-25 | — | — | US | disclosed |
| EP-4146629-A1 | DIMERS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | The Feinstein Institutes for Medical Research (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-115515937-A | Dimers for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-12-23 | — | — | CN | disclosed |
| US-20220372022-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2013067248-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20110112114-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20040077600-A1 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | TUNG ROGER D (US) | 2004-04-22 | — | — | US | disclosed |
| US-6608067-B1 | Treating hepatitis C viral infection | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-19 | — | — | US | disclosed |
| EP-1066247-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999050230-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-10-07 | — | — | WO | disclosed |